Veru announces appointment of joel batten to lead u.s. infectious disease franchise to focus on hospitalized covid-19 patients

Miami, may 18, 2022 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company focused on developing novel medicines for covid-19 and other viral and ards-related diseases and for the management of breast and prostate cancers, today announced the appointment of joel batten as executive vice president and head of its u.s. infectious disease franchise effective may 23, 2022.
VERU Ratings Summary
VERU Quant Ranking